Hemostatic risk factors and arterial thorombotic disease

Thrombosis and Haemostasis

Volumn 85, Issue 4, 2001, Pages 584-595

  Reiner, A P ^a   Siscovick, D S ^a   Rosendaal, F R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BEZAFIBRATE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IIIA; HOMOCYSTEINE; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOCYTE RECEPTOR; THROMBOMODULIN; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HEMOSTASIS; HOMOCYSTINURIA; HUMAN; ISCHEMIC HEART DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN POLYMORPHISM; REVIEW; SCREENING; STROKE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 0035070827     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615638     Document Type: Review

References (186)

1. Stability and instability: Two faces of coronary atherosclerosis
2. Thrombi in acute coronary syndromes. Revisited and revised
3. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work
4. Antithrombotic agents in the secondary and primary prevention of cardiovascular diseases in high and usual risk individuals
5. Novel risk factors and markers for coronary disease
6. Novel risk factors for atherosclerosis
7. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
8. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analysis of prospective studies
9. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update
10. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
11. Fibrinogen and cardiovascular risk markers
12. Lowering fibrinogen levels: Clinical update
13. Regulation of fibrinogen assembly. Transfection of hepG2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen
14. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis
15. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM study
16. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute coronary disease
17. Genetic variation in the promoter region of the β-fibrinogen gene is associated with ischemic stroke in a Japanese population
18. A common mutation (G-455→A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on The Copenhagen City Heart Study
19. Positive association of the β fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
20. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
21. Coagulation factor VII and the risk of coronary heart disease in healthy men
22. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
23. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study
24. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS)
25. Coagulation factor VII, dietary fat and blood lipids: A review
26. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies
27. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
28. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype
29. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study
30. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
31. Polymorphisms of the factor VII gene and circulating FVIIC levels in relation to acute cerebrovascular disease and post stroke mortality
32. Factor VIII, ABO blood group, and the incidence of ischaemic heart disease
33. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study
34. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study
35. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
36. Von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis
37. Mortality and causes of death in Dutch haemophiliacs, 1973-1986
38. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986
39. Role of clotting factor VIII in effect on von Willebrand factor on occurrence of deep-venous thrombosis
40. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males
41. Familial clustering of factor VIII and von Willebrand factor levels
42. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
43. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVAL34Leu) affects cross-linking activity
44. Association of a common polymorphism in the factor XIII gene with myocardial infarction
45. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males
46. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
47. Association of a common polymorphism in the factor XIII gene with venous thrombosis
48. Factor XIII Val34Leu: A novel association with primary intracerebral hemorrhage
49. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
50. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease
51. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S
52. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency
53. Prothrombotic states in young people with idiopathic stroke. A prospective study
54. Antithrombin, protein C, and protein S levels in 127 consecutive young adults with ischemic stroke
55. Coagulation disorders in young adults with acute cerebral ischemia
56. Inherited prothrombotic conditions and premature ischemic stroke. Sex differences in the association with factor V Leiden
57. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis
58. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood
59. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children
60. Inherited prothrombotic states and ischaemic stroke in childhood
61. Factor V Leiden, prothrombin 20210 G→A and the MTHFR C677T mutations in childhood stroke
62. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
63. Mutation in blood coagulation factor V associated with resistance to activated protein C
64. Myocardial infarction associated with homozygous resistance to activated protein C
65. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance
66. Arg506Gln factor V mutation in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction
67. Evidence against heterozygous coagulation factor V 1691 GA mutation for coronary artery disease and myocardial infarction
68. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
69. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease
70. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease
71. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
72. Premature ischaemic heart disease and the gene for coagulation factor V
73. Prothrombotic genetic risk factors in young survivors of myocardial infarction
74. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease
75. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
76. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
77. Factor V Leiden gene mutation and thrombin generation in relation to development of stroke
78. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients
79. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults
80. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A)
81. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke
82. Activated protein C resistance, factor V Leiden and peripheral vascular disease
83. Activated protein C resistance in patients with peripheral vascular disease
84. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease
85. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease
86. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease
87. Genetic determinants of hemostasis phenotypes in Spanish families
88. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
89. Geographic distribution of the 20210 G to A prothrombin variant
90. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease
91. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease
92. The prevalence of the prothrombin 20210 G→A mutation is not increased in angiographically confirmed coronary artery disease
93. The prothrombin 20210A allele and its association with myocardial infarction
94. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
95. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease
96. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
97. Thrombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young
98. 3
99. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
100. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease
101. A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease
102. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population
103. A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study
104. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter intervention: A case-controlled study
105. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction
106. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
107. A1/A2 polymorphism, platelet activation, and incidence of coronary heart disease
108. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans
109. A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke
110. A2 and ischemic stroke risk
111. HPA-1 genotype in arterial thrombosis - Role of HPA-1b polymorphism in platelet function
112. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke
113. A2 polymorphism. The Framingham Offspring Study
114. A polymorphisms display different sensitivities to agonists
115. A2 polymorphism
116. A2): No association with platelet fibrinogen binding
117. 3 enhances outside-in signaling and adhesive functions
118. A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly
119. 2 gene coding sequence
120. 1 density
121. 2 gene in platelet GP Ia collagen receptor expression and function. Effect in thrombembolic diseases
122. 807T gene polymorphism with non-fatal myocardial infarction in younger patients
123. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study
124. 1 might be a genetic risk factor for the development of stroke in younger patients
125. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women
126. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction
127. Polymorphism of human platelet glycoprotein Iba results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region: Structure/function implications
128. 145 dimorphism in platelet glycoprotein Ibα in Italian population
129. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbα express HPA-2 epitopes and show equal binding of von Willebrand factor
130. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation
131. Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease
132. Association between platelet glycoprotein Ibα genotype and ischemic cerebrovascular disease
133. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
134. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
135. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
136. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women
137. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
138. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries
139. Association of fibrinolytic parameters with early atherosclerosis: The ARIC study - Atherosclerosis Risk in Communities Study
140. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy
141. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels
142. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction
143. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in hepG2 cells
144. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
145. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
146. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
147. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
148. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
149. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
150. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
151. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background
152. Homocysteine and atherothrombosis
153. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
154. Hyperhomocysteinemia, atherosclerosis and thrombosis
155. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual?
156. Plasma homocysteine in the acute and convalescent phases after stroke
157. Serial measures of plasma homocyst(e)ine after acute myocardial infarction
158. Common methylene-tetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The results of a meta-analysis
159. The role of lipoprotein(a) in atherosclerosis and thrombosis
160. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein concentrations
161. Lipoprotein Lp(a) excess and coronary heart disease
162. Lipoprotein(a), fibrin-binding, and plasminogen activator
163. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis
164. Lipoprotein(a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation
165. Lipoprotein(a) and stroke
166. Lipoprotein [Lp(a)] and peripheral vascular disease
167. Lipoprotein(a) levels and risk of coronary heart disease in men
168. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol, and other risk factors; Results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)
169. Apoliproteins and ischaemic heart disease: Implications for screening
170. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study
171. A prospective case control study of elevated lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants
172. Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants
173. A prospective study of lipoprotein(a) and the risk of myocardial infarction
174. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study
175. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk
176. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)
177. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study
178. LPA gene: Interaction between the apolipoprotein(a) size (`kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level
179. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study
180. Thrombomodulin gene mutations associated with myocardial infarction
181. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men
182. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction
183. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography
184. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on Fibrongen
185. Genetic susceptibility to death from coronary heart disease in a study of twins
186. The TDT and other family-based tests for linkage disequilibrium and association